ICER report highlights patent review as key to lowering GLP-1 drug costs
The Institute for Clinical and Economic Review (ICER) has released a white paper detailing strategies to enhance the affordability of GLP-1 obesity drugs, including the improvement of patent-quality review processes. Read More »
Alerts Sign-up